Urethral stricture treatment by HCT, granted Japanese patent


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Biomaterial research facility of JBM in Tokyo
Hybrid Cell Therapy or HCT is a painless & simple day-care procedure suitable for global reach

Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as a carrier, has been granted a patent in Japan. A longer duration of relief to patients who had a recurrence of the disease after earlier conventional treatments have been reported by this method called “Bees-Haus.” 

Male urethra, a tubular passage to let the urine out from urinary bladder, when affected with narrowing or stricture of the lumen, causes difficulty in avoiding urine, urinary retention, and pain during micturition. Treatments include dilatation with balloon or urethrotomy under endoscopy at early stages and surgical urethroplasty under general anesthesia using patient’s autologous oral/buccal tissue graft in severe disease or long segment stricture. After surgery, for a while, patients pass urine through catheter drainage and complications such as stricture recurrence, urinary tract infection, impotence, sexual dysfunction, and incontinence, have been reported (Gallegos & Santucci F1000Res. 2016;5-2913 & Barbagli et al. European Urology Supplements 2016;15-1).

Bees-Haus method of cell therapy could be performed in two-steps, both as a daycare procedure. A small bit of patient’s oral tissue is taken, cells cultured in the lab, and transplanted through endoscopy. Very simple and convenient for urologists and relatively painless to patients with shorter hospital stays reducing healthcare costs and burden, because of lesser complications, making Bees-Haus easy to adopt. A larger multicentric study is under a proposal by JBM Inc, to validate its efficacy to make this a routine procedure to benefit many patients with a better quality of life.

Urethral stricture disease occurs mainly in men and its incidence climbs sharply after 55 years in the western population. An estimated 0.6% in susceptible populations are affected in which 4% of male patients require an interventional procedures. Annually 200 million USD is spent in the USA for urethral stricture treatment, which doesn’t include the cost of medication. The Americas hold the largest share in the global urethral stricture market, followed by Europe and the Asia Pacific. JBM has applied for patents worldwide including USA, EU, United Kingdom and are looking for country-wise partners for technology licensing out. JBM also established a biomaterial laboratory to develop novel scaffolds for various applications in regenerative medicine, implants, and medical devices in Tokyo.

Tags : #UrethralStrictureTreatment #JBMInc #BeesHaus #USA #UK #EU #UrinnaryRetention

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026